23andMe's Anne Wojcicki writes in an opinion piece at Stat News that people can understand their genetic risk information without the input of experts.
There's an increase in genetic testing for breast cancer risk in Northern Ireland, BBC News reports, adding that better support for those tested is also needed.
The 4,000-participant study will use a digital enrollment platform and will provide free genetic testing as well as support from doctors and genetics experts.
FDA's blessing for 23andMe's test that gauges select BRCA1/2 variants has the cancer community worried about whether consumers will understand its limitations.
23andMe has gotten the OK from the US Food and Drug Administration for its genetic health risk report on three mutations that increase breast cancer risk.
The consumer genomics firm says employer benefits programs could expand access to BRCA1/2, Lynch syndrome, and FH genetic testing in the general population.
The company discussed its efforts to grow adoption of its products during a call to discuss second quarter financial results for fiscal year 2018.
The LOHGIC algorithm is currently being used to analyze tumor sequencing assay results as part of the Rutgers Cancer Institute's precision medicine program.
The Seoul-based company also recently raised $1.9 million in series B funding and is targeting between $7 million and $8 million to close the round.
NGeneBio said this week that its next-generation sequencing panel has been approved as an IVD, the first NGS test to be cleared in Korea.
Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.
The New York Times reports on the shifting interpretations of what some genetic variants mean over time.
MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.
In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.